Autopsy Case of Gaucher Disease Type I in a Patient on Enzyme Replacement Therapy. Comments on the Dynamics of Persistent Storage Process

Overview

Journal J Inherit Metab Dis

Publisher Wiley

Date 2009 Jun 27

PMID 19557545

Citations 7

Authors

H Hulkova

J Ledvinova

H Poupetova

A Kohout

V Malinova

M Elleder

Affiliations

Soon will be listed here.

Abstract

We report a female patient with Gaucher disease (GD) type I on ERT (imiglucerase) for 5 years, which led to a significant general improvement. Aged 59 years she underwent an episode of altitude sickness followed by sepsis, disseminated intravascular coagulation, and multiorgan failure. She succumbed to a cerebral haemorrhage. Autopsy revealed liver cholestatic cirrhosis and multifocal liver carcinoma with immunophenotype compatible with cholangiocarcinoma. Analysis of the storage process revealed its absence or very low levels in the majority of liver and spleen macrophages. Gaucher cells (GCs) were seen only as occasional aggregates of various sizes in these organs. GCs were seen also in the leptomeninx of the cerebellum and as infrequent perivascular clusters in both the grey and white cerebral matters. Bone marrow was heavily infiltrated with GCs, especially in the adipocyte-rich part. GCs in this location displayed varied degrees of cytoplasmic vacuolation unrelated to the lysosomal compartment, caused by droplets of triglyceride, and interpreted as due to resorption of fragments of altered white adipocytes. All these observations point to the relative efficacy of ERT in covering the standard substrate load, which should not be exceeded as it would lead to the evolution of mature GCs. The results are discussed in relation to our recently published hypothesis on GD cell pathology.

Citing Articles

Neuropathological Features of Gaucher Disease and Gaucher Disease with Parkinsonism.

Furderer M, Hertz E, Lopez G, Sidransky E Int J Mol Sci. 2022; 23(10).

PMID: 35628652 PMC: 9147326. DOI: 10.3390/ijms23105842.

Treatment of lysosomal storage disorders: successes and challenges.

Hollak C, Wijburg F J Inherit Metab Dis. 2014; 37(4):587-98.

PMID: 24820227 DOI: 10.1007/s10545-014-9718-3.

Gaucher disease and malignancy: a model for cancer pathogenesis in an inborn error of metabolism.

Mistry P, Taddei T, Dahl S, Rosenbloom B Crit Rev Oncog. 2013; 18(3):235-46.

PMID: 23510066 PMC: 4437216. DOI: 10.1615/critrevoncog.2013006145.

Adipocytes participate in storage in α-galactosidase deficiency (Fabry disease).

Hulkova H, Elleder M J Inherit Metab Dis. 2010; 33 Suppl 3:S297-300.

PMID: 20628902 PMC: 3757258. DOI: 10.1007/s10545-010-9160-0.

Expanding spectrum of the association between Type 1 Gaucher disease and cancers: a series of patients with up to 3 sequential cancers of multiple types--correlation with genotype and phenotype.

Lo S, Stein P, Mullaly S, Bar M, Jain D, Pastores G Am J Hematol. 2010; 85(5):340-5.

PMID: 20425796 PMC: 2875938. DOI: 10.1002/ajh.21684.

References

Zimran A, Liphshitz I, Barchana M, Abrahamov A, Elstein D . Incidence of malignancies among patients with type I Gaucher disease from a single referral clinic. Blood Cells Mol Dis. 2005; 34(3):197-200. DOI: 10.1016/j.bcmd.2005.03.004. View

Buchsel R, Brambs H, Oehlert M, Matern S . [Coincidence of Gaucher disease with primary hepatocellular carcinoma]. Leber Magen Darm. 1991; 21(3):126, 129-30. View

Elleder M . Glucosylceramide transfer from lysosomes--the missing link in molecular pathology of glucosylceramidase deficiency: a hypothesis based on existing data. J Inherit Metab Dis. 2006; 29(6):707-15. DOI: 10.1007/s10545-006-0411-z. View

Keslova-Veselikova J, Hulkova H, Dobrovolny R, Asfaw B, Poupetova H, Berna L . Replacement of alpha-galactosidase A in Fabry disease: effect on fibroblast cultures compared with biopsied tissues of treated patients. Virchows Arch. 2008; 452(6):651-65. PMC: 2956889. DOI: 10.1007/s00428-008-0586-9. View

Markwell M, Haas S, Tolbert N, Bieber L . Protein determination in membrane and lipoprotein samples: manual and automated procedures. Methods Enzymol. 1981; 72:296-303. DOI: 10.1016/s0076-6879(81)72018-4. View

Deegan P, Moran M, McFarlane I, Schofield J, Boot R, Aerts J . Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease. Blood Cells Mol Dis. 2005; 35(2):259-67. DOI: 10.1016/j.bcmd.2005.05.005. View

Erjavec Z, Hollak C, De Vries E . Hepatocellular carcinoma in a patient with Gaucher disease on enzyme supplementation therapy. Ann Oncol. 1999; 10(2):243. DOI: 10.1023/a:1008306414822. View

Daniels L, Glew R, RADIN N, Vunnam R . A revised fluorometric assay for Gaucher's disease using conduritol-beta-epoxide with liver as the source of Beta-glucosidase. Clin Chim Acta. 1980; 106(2):155-63. DOI: 10.1016/0009-8981(80)90168-0. View

Leinekugel P, Michel S, Conzelmann E, Sandhoff K . Quantitative correlation between the residual activity of beta-hexosaminidase A and arylsulfatase A and the severity of the resulting lysosomal storage disease. Hum Genet. 1992; 88(5):513-23. DOI: 10.1007/BF00219337. View

10.

de Fost M, Vom Dahl S, Weverling G, Brill N, Brett S, Haussinger D . Increased incidence of cancer in adult Gaucher disease in Western Europe. Blood Cells Mol Dis. 2005; 36(1):53-8. DOI: 10.1016/j.bcmd.2005.08.004. View

11.

Blanchette-Mackie E, Briggs T, CHERNICK S, SCOW R . Lipolysis of serum-activated triacylglycerol at the surface of J774.1 macrophages. A biochemical--electron-microscopic study. Cell Tissue Res. 1986; 244(1):95-105. DOI: 10.1007/BF00218386. View

12.

Soffer D, Yamanaka T, Wenger D, Suzuki K . Central nervous system involvement in adult-onset Gaucher's disease. Acta Neuropathol. 1980; 49(1):1-6. DOI: 10.1007/BF00692212. View

13.

Cox T . Biomarkers in lysosomal storage diseases: a review. Acta Paediatr Suppl. 2005; 94(447):39-42. DOI: 10.1111/j.1651-2227.2005.tb02109.x. View

14.

Neudorfer O, Hadas-Halpern I, Elstein D, Abrahamov A, Zimran A . Abdominal ultrasound findings mimicking hematological malignancies in a study of 218 Gaucher patients. Am J Hematol. 1997; 55(1):28-34. DOI: 10.1002/(sici)1096-8652(199705)55:1<28::aid-ajh5>3.0.co;2-5. View

15.

Brady R, Pentchev P, GAL A, Hibbert S, DEKABAN A . Replacement therapy for inherited enzyme deficiency. Use of purified glucocerebrosidase in Gaucher's disease. N Engl J Med. 1974; 291(19):989-93. DOI: 10.1056/NEJM197411072911901. View

16.

Xu R, Mistry P, McKenna G, Emre S, Schiano T, Bu-Ghanim M . Hepatocellular carcinoma in type 1 Gaucher disease: a case report with review of the literature. Semin Liver Dis. 2005; 25(2):226-9. DOI: 10.1055/s-2005-871201. View

17.

Hill S, Reinig J, Barranger J, Fink J, Shawker T . Gaucher disease: sonographic appearance of the spleen. Radiology. 1986; 160(3):631-4. DOI: 10.1148/radiology.160.3.3526400. View

18.

Conradi N, Kalimo H, SOURANDER P . Reactions of vessel walls and brain parenchyma to the accumulation of Gaucher cells in the Norrbottnian type (type III) of Gaucher disease. Acta Neuropathol. 1988; 75(4):385-90. DOI: 10.1007/BF00687792. View

19.

Landgren O, Turesson I, Gridley G, Caporaso N . Risk of malignant disease among 1525 adult male US Veterans with Gaucher disease. Arch Intern Med. 2007; 167(11):1189-94. DOI: 10.1001/archinte.167.11.1189. View

20.

Daniels L, Coyle P, Glew R, RADIN N, Labow R . Brain glucocerebrosidase in Gaucher's disease. Arch Neurol. 1982; 39(9):550-6. DOI: 10.1001/archneur.1982.00510210020005. View